Literature DB >> 17449248

Structure-activity relationship, kinetic mechanism, and selectivity for a new class of ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitors.

Ara H Mermerian1, April Case, Ross L Stein, Gregory D Cuny.   

Abstract

3-Amino-2-keto-7H-thieno[2,3-b]pyridin-6-one derivatives were discovered as moderately potent inhibitors of ubiquitin C-terminal hydrolase-L1 (UCH-L1) utilizing an assay that measures hydrolysis of the fluorogenic substrate Ub-AMC. SAR studies revealed that both the carboxylate at the 5-position and the 6-pyridone ring were critical for inhibitory activity. Furthermore, activity was dependent on the nature of the ketone substituent at the 2-position, with 4-Me-Ph and 2-naphthyl being best. Kinetic mechanism studies revealed that these compounds were uncompetitive inhibitors of UCH-L1, binding only to the Michaelis-complex and not to free enzyme. The active compounds were selective for UCH-L1, exhibiting neither inhibition of other cysteine hydrolases (e.g., UCH-L3, papain, isopeptidase T, caspase-3, and tissue transglutaminase) nor cytotoxicity in N2A cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17449248     DOI: 10.1016/j.bmcl.2007.04.027

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  27 in total

Review 1.  Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes.

Authors:  Francisca E Reyes-Turcu; Karen H Ventii; Keith D Wilkinson
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

Review 2.  One hundred years of Meldrum's acid: advances in the synthesis of pyridine and pyrimidine derivatives.

Authors:  Victoria V Lipson; Nikolay Yu Gorobets
Journal:  Mol Divers       Date:  2009-04-21       Impact factor: 2.943

3.  Ubiquitin C-Terminal Hydrolase L1: Biochemical and Cellular Characterization of a Covalent Cyanopyrrolidine-Based Inhibitor.

Authors:  Aaron D Krabill; Hao Chen; Sajjad Hussain; Chao Feng; Ammara Abdullah; Chittaranjan Das; Uma K Aryal; Carol Beth Post; Michael K Wendt; Paul J Galardy; Daniel P Flaherty
Journal:  Chembiochem       Date:  2019-11-07       Impact factor: 3.164

Review 4.  Emerging role of DUBs in tumor metastasis and apoptosis: Therapeutic implication.

Authors:  Mingjing He; Zhuan Zhou; George Wu; Qianming Chen; Yong Wan
Journal:  Pharmacol Ther       Date:  2017-03-06       Impact factor: 12.310

5.  Downregulated UCHL1 Accelerates Gentamicin-Induced Auditory Cell Death via Autophagy.

Authors:  Yeon Ju Kim; Kyung Kim; Yun Yeong Lee; Oak-Sung Choo; Jeong Hun Jang; Yun-Hoon Choung
Journal:  Mol Neurobiol       Date:  2019-04-30       Impact factor: 5.590

6.  Isopeptidases in anticancer therapy: looking for inhibitors.

Authors:  Andrea Sgorbissa; Harish Potu; Claudio Brancolini
Journal:  Am J Transl Res       Date:  2010-05-10       Impact factor: 4.060

Review 7.  Deubiquitinases (DUBs) and DUB inhibitors: a patent review.

Authors:  Pershang Farshi; Rahul R Deshmukh; Joseph O Nwankwo; Richard T Arkwright; Boris Cvek; Jinbao Liu; Q Ping Dou
Journal:  Expert Opin Ther Pat       Date:  2015-06-16       Impact factor: 6.674

8.  Characterization and structural studies of the Plasmodium falciparum ubiquitin and Nedd8 hydrolase UCHL3.

Authors:  Katerina Artavanis-Tsakonas; Wilhelm A Weihofen; John M Antos; Bradley I Coleman; Christy A Comeaux; Manoj T Duraisingh; Rachelle Gaudet; Hidde L Ploegh
Journal:  J Biol Chem       Date:  2009-12-30       Impact factor: 5.157

9.  Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells.

Authors:  Helena Mistry; Grace Hsieh; Sara J Buhrlage; Min Huang; Eunmi Park; Gregory D Cuny; Ilene Galinsky; Richard M Stone; Nathanael S Gray; Alan D D'Andrea; Kalindi Parmar
Journal:  Mol Cancer Ther       Date:  2013-10-15       Impact factor: 6.261

Review 10.  Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases.

Authors:  Mariola J Edelmann; Benjamin Nicholson; Benedikt M Kessler
Journal:  Expert Rev Mol Med       Date:  2011-11-17       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.